Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CHIMERIC ANTIGEN RECEPTOR TARGETING MESOTHELIN, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/284053
Kind Code:
A1
Abstract:
A chimeric antigen receptor targeting mesothelin, and the use thereof. The chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular domain which are sequentially linked, wherein the extracellular region comprises an extracellular signaling peptide, an antigen recognition region and a hinge region, the antigen recognition region is fully human anti-mesothelin scFv, and the intracellular domain comprises an intracellular signaling domain and an intracellular costimulatory signal domain. The chimeric antigen receptor T cell has a very strong killing activity on mesothelin positive tumor cells, does not have immunogenicity by using a fully-humanized antibody as scfv, and can be repeatedly administrated, thereby enhancing the therapeutic effect of the CAR-T cell.

Inventors:
LI JUN (CN)
GUO ZHIGANG (CN)
Application Number:
PCT/CN2021/112515
Publication Date:
January 19, 2023
Filing Date:
August 13, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NANJING BLUE SHIELD BIOTECH CO LTD (CN)
International Classes:
C07K19/00; A61K39/00; C12N5/10; C12N15/62; C12N15/867
Domestic Patent References:
WO2021130250A12021-07-01
WO2019063018A12019-04-04
Foreign References:
CN111683962A2020-09-18
CN111187352A2020-05-22
CN111057158A2020-04-24
CN109306014A2019-02-05
CN110746508A2020-02-04
CN111349165A2020-06-30
Other References:
WEI JIANSHU; GUO YELEI; WANG YAO; WU ZHIQIANG; BO JIAN; ZHANG BIN; ZHU JUN; HAN WEIDONG: "Clinical development of CAR T cell therapy in China: 2020 update", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 18, no. 4, 1 April 2021 (2021-04-01), London, pages 792 - 804, XP037390040, ISSN: 1672-7681, DOI: 10.1038/s41423-020-00555-x
Attorney, Agent or Firm:
NANJING SUGAO PATENT AND TRADEMARK FIRM (ORDINARY PARTNERSHIP) (CN)
Download PDF: